News
- 2024/11/01
- Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advanced ROS1-positive Non-Small Cell Lung Cancer.
- 2024/10/10
- Annual update has been made to our Sustainability site.
- 2024/05/08
- Received ‘AA’ for the first time in MSCI ESG Ratings